Cancer–neuronal crosstalk and the startups working to silence it
Elie Dolgin • February 7, 2020
Investors back ‘cancer neuroscience’ outfits as the field breaks out from academia.
Continue reading here.
Molecular signatures of aging are changing how conservationists assess population health, resilience and risk.
Paul Mischel is championing the importance of odd rings of DNA in tumors — and their promise as targets for cancer therapy.